Cited by 520Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerCancer Mechanisms and Therapy

The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Sabapathy, Kanaga, Lane, David P.·2018·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2017.151

Open this paper in CoChat — free account

Abstract

TP53, which encodes the tumour-suppressor protein p53, is the most frequently mutated gene across all cancer types. The presence of mutant p53 predisposes to cancer development, promotes the survival of cancer cells, and is associated with ineffective therapeutic responses and unfavourable prognoses. Despite these effects, no drug that abrogates the oncogenic functions of mutant p53 has yet been approved for the treatment of cancer. Current investigational therapeutic strategies are mostly aimed at restoring the wild-type activity of mutant p53, based on the assumption that all p53 mutants are functionally equal. Our increasing knowledge of mutant forms of p53, however, supports the antithetical hypothesis that not all p53 mutants have equivalent cellular effects; hence, a judicious approach to therapeutic targeting of mutant p53 is required. In this Review, we propose a categorization of the major classes of p53 mutants based on their functionality in tumour suppression and response to therapy. The emerging picture is that the mutations across TP53 form a 'rainbow of mutants', with varying degrees of functionality and different pathobiological consequences, necessitating the use of diverse therapeutic strategies to selectively target specific classes of mutation. The utility of this knowledge of TP53 mutations in developing selective therapeutic options, and in facilitating clinical decision-making is discussed.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2017.151

Cites

182 of 182 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Self-citation
p53 in health and disease
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,351
Self-citation

Flagged first, then by citations

Show all 178 references

Sorted by citations

Items 301–400 of 520

Targeting colorectal cancer with Herba Patriniae and Coix seed: Network pharmacology, molecular docking, and in vitro validation
Wang, C.-L., Yang, B.-W., Wang, X., Xue, C., Li, W., Zhai, H.-Y., Wu, Y., Cui, M.-Y., Wu, J., Meng, Q., et al. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i8.3539 · Cited by 6
Research progress on gene mutations and drug resistance in leukemia
Ma, X., Xu, J., Wang, Y., Fleishman, J. S., Bing, H., Yu, B., Li, Y., Bo, L., Zhang, S., Chen, Z., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101195 · Cited by 7
Small molecules that targeting p53 Y220C protein: mechanisms, structures, and clinical advances in anti-tumor therapy
Xu, J., Yuan, J., Wang, W., Zhu, X., Li, J., Ma, Y., Liu, S., Feng, J., Chen, Y., Lu, T., et al. (2025) · Molecular Diversity · doi:10.1007/s11030-024-11045-x · Cited by 6
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials
Zhou, D. D.-X., Lord, S. J., Lin, F. P. Y., Cooper, W. A., Zaheed, M., Simes, R. J., John, T., & Lee, C. K. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108891 · Cited by 6
TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC
Feng, H., Xu, H., Shi, X., Ding, G., Yan, C., Li, L., Jian, Z., Yang, X., Guo, H., Feng, L., et al. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807147 · Cited by 6
Prognostic significance of TP53 and PIK3CA mutations analyzed by next-generation sequencing in breast cancer
Choi, J., Yu, J., Jung, M.-J., Jekal, J., Kim, K. S., & Jung, S. U. (2023) · Medicine · doi:10.1097/md.0000000000035267 · Cited by 6
Mutant p53 Gain-of-Function Induces Migration and Invasion through Overexpression of miR-182-5p in Cancer Cells
Madrigal, T., Ortega‐Bernal, D., Herrera, L. A., la Rosa, C. H. G.-D., Domínguez-Gómez, G., Aréchaga-Ocampo, E., & Díaz‐Chávez, J. (2023) · Cells · doi:10.3390/cells12202506 · Cited by 6
ARTS and small-molecule ARTS mimetics upregulate p53 levels by promoting the degradation of XIAP
Abbas, R., Hartmann, O., Asiss, D. T., Abbas, R., Kagan, J., Kim, H.-T., Oren, M., Diefenbacher, M. E., Orian, A., & Larisch, S. (2024) · APOPTOSIS · doi:10.1007/s10495-024-01957-2 · Cited by 6
Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment‐naïve breast cancer
Chen, S., Tse, K., Lu, Y., Chen, S., Tian, Y., Tan, K. T., & Li, C. (2024) · Cancer Medicine · doi:10.1002/cam4.7384 · Cited by 5
How Recent Advances in Biology of Waldenström’s Macroglobulinemia May Affect Therapy Strategy
Baron, M., Simon, L., Poulain, S., & Leblond, V. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0768-4 · Cited by 6
D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy
Barra, J., Cerda‐Infante, J., Sandoval, L., Gajardo-Meneses, P., Henriquez, J. F., Labarca, M., Metz, C., Venegas, J., Retamal, C., Oyanadel, C., et al. (2021) · Cancers · doi:10.3390/cancers13143622 · Cited by 6
Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression
Casalin, I., Stefano, A. D., Ceneri, E., Cappellini, A., Finelli, C., Curti, A., Paolini, S., Parisi, S., Zannoni, L., Boultwood, J., et al. (2024) · Advances in Biological Regulation · doi:10.1016/j.jbior.2024.101014 · Cited by 6
A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms
Abdulbaki, R., & Pullarkat, S. T. (2024) · Current Oncology · doi:10.3390/curroncol31050175 · Cited by 6
p53 Tumor Suppressor: Functional Regulation and Role in Gene Therapy
Farooq, Z., Wani, S., Ragunathrao, V. A. B., Kochhar, R. K., & Anwar, M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105029 · Cited by 7
The potential mechanism of extracellular high mobility group box-1 protein mediated p53 expression in immune dysfunction of T lymphocytes
Luan, Y., Jia, M., Zhang, H., Zhu, F., Dong, N., Feng, Y., Wu, M. T., Tong, Y., & Yao, Y.-M. (2017) · Oncotarget · doi:10.18632/oncotarget.22913 · Cited by 6
Calpain‐mediated cleavage of p53 in human cytomegalovirus‐infected lung fibroblasts
Chen, Z., Boor, P. J., Finnerty, C. C., Herndon, D. N., & Albrecht, T. (2018) · FASEB BioAdvances · doi:10.1096/fba.1028 · Cited by 6
The CRISPR-Cas revolution in head and neck cancer: a new era of targeted therapy
Hashemi, M., Khanaghah, X. M., & Nahand, J. S. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01612-2 · Cited by 5
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup
Fischer, N. W., Ong, N., Laverty, B., Psarianos, P., Giovino, C., Alon, N., Montellier, E., Hainaut, P. L., Maxwell, K. N., Kratz, C. P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63528-6 · Cited by 9
p53 regulates glucose metabolic reprogramming in MASLD-related hepatocellular carcinoma via modulating mitochondrial pyruvate carriers
Wang, Z., Tian, F., Wang, Y., Meng, X., Wang, Q., Cao, L., He, Z., & Ma, X. (2025) · Hepatology International · doi:10.1007/s12072-025-10939-8 · Cited by 5
Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma
Yu, J., He, Q., Yan, Y., Liu, K., Xie, R., Ma, J., & Wang, L. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06882-9 · Cited by 5
Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies
Wu, H. H., Leng, S., Eisenstat, D. D., Sergi, C. M., & Leng, R. P. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00907-x · Cited by 6
p53 Deficiency-Dependent Oncogenicity of Runx3
Ito, K., Otani, S., & Date, Y. (2023) · Cells · doi:10.3390/cells12081122 · Cited by 6
Taxifolin attenuates cisplatin-induced kidney damage in rats via suppressing p53 and iNOS
Akçakavak, G., Karataş, Ö., ÇELİK, Z., Tural, A., Dağar, O., Jabbar, A. A., KILINÇ, B., & Tuzcu, M. (2024) · Etlik Veteriner Mikrobiyoloji Dergisi · doi:10.35864/evmd.1458328 · Cited by 5
Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine
Dinić, J., Stojanov, S. J., Dragoj, M., Grozdanić, M., Podolski-Renić, A., & Pešić, M. (2024) · Life · doi:10.3390/life14091142 · Cited by 6
TP53 mutation status and consensus molecular subtypes of colorectal cancer in patients from Rwanda
Nzitakera, A., Uwamariya, D., Kato, H., Surwumwe, J. B., Mbonigaba, A., Ndoricyimpaye, E. L., Uwamungu, S., Manirakiza, F., Ndayisaba, M. C., Ntakirutimana, G., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13009-8 · Cited by 5
Survival outcome prediction of esophageal squamous cell carcinoma patients based on radiomics and mutation signature
Yan, Z., Yan, Z., Chen, G., Wu, C., Wu, C., Zhou, Q., Wang, G., Li, Y., Jia, M., Zhuang, X., et al. (2025) · Cancer Imaging · doi:10.1186/s40644-024-00821-5 · Cited by 5
Therapeutic Potential of Translational Readthrough at Disease‐Associated Premature Termination Codons From Tumor Suppressor Genes
Torices, L., Nunes‐Xavier, C. E., & Pulido, R. (2025) · IUBMB Life · doi:10.1002/iub.70018 · Cited by 6
EDUCACIÓN PARA EL BILINGÜISMO EN CONTEXTO MONOLINGÜE: DOS LENGUAS CONECTADAS DESDE EL CURRÍCULO
Ordóñez, C. L. (2010) · Elia · Cited by 5
Deep Molecular and In Silico Protein Analysis of p53 Alteration in Myelodysplastic Neoplasia and Acute Myeloid Leukemia
Madarász, K., Mótyán, J. A., Bedekovics, J., Miltényi, Z., Újfalusi, A., Méhes, G., & Mokánszki, A. (2022) · Cells · doi:10.3390/cells11213475 · Cited by 5
Case Report: Genetic profiling of small intestine metastasis from poorly differentiated non-small cell lung cancer: report of 2 cases and literature review of the past 5 years
Wang, M., Chen, G., Luo, J., Fan, Z., Liu, Y., Xie, C., & Gong, Y. Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1265749 · Cited by 5
Arsenic trioxide extends survival of Li–Fraumeni syndrome mimicking mouse
Li, J., Xiao, S., Shi, F., Song, H., Wu, J., Zheng, D., Chen, X., Tan, K. W., & Lu, M. M. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06281-2 · Cited by 5
Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
Kobayashi, K. (2023) · Journal of Respiration · doi:10.3390/jor3040021 · Cited by 6
Suit the Remedy to the Case: An Activatable DNA Damage Initiator for Postsurgical Therapy of Glioblastoma with TP53 Mutations
Hua, Y., Cao, P., Wang, W., Chen, H., Hu, Z., Yang, S., Ge, Y., Heng Jun, G. A. O., Lin, F., & Wu, H. (2024) · ACS Materials Letters · doi:10.1021/acsmaterialslett.4c00058 · Cited by 5
Telomerase reverse transcriptase mutation and the p53 pathway in T1 urinary bladder cancer
Jahnson, S., Söderkvist, P., Aljabery, F. A.-S., & Olsson, H. (2021) · British Journal of Urology · doi:10.1111/bju.15490 · Cited by 5
Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours
Dhaka, B., & Sabarinathan, R. (2021) · BMC Cancer · doi:10.1186/s12885-021-08362-x · Cited by 5
Detection of a novel panel of 24 genes with high frequencies of mutation in gastric cancer based on next-generation sequencing
Zeng, H.-H., Yang, Z. R., Qiu, Y., Bashir, S., Li, Y., & Xu, M. Q. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i15.4761 · Cited by 5
Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5‐mediated p53 degradation blockage
Li, J., Wang, Y., Zhang, X., Yang, X., Qi, Q., Mi, Q., Feng, M., Wang, Y., Wang, C., Li, P., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1149 · Cited by 5
In silico identification of prospective p53-MDM2 inhibitors from ASINEX database using a comprehensive molecular modelling approach
Kotadiya, D. D., Prajapati, A., Patel, D. A., Thakur, P., Nair, R., & Patel, H. D. (2025) · Scientific Reports · doi:10.1038/s41598-025-10589-8 · Cited by 4
Integrated molecular and microenvironmental drivers of drug resistance in gastrointestinal cancers: mechanisms, immunotherapy challenges, and precision strategies
Xu, H., Lu, J., Wu, J., Zhang, K., Zhou, X., Gao, Z., Feng, J., Zhuang, Z., & Zhong, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1675745 · Cited by 4
Molecular Landscape of TP53 / RB1 Co‐Altered Tumors Uncovers Emerging Therapeutic Vulnerabilities
Li, X., Ye, M., Huang, X., Huang, Z., Zhu, J., He, Z., Zhao, Z., Hou, J., & Wei, S. (2026) · Genes Chromosomes and Cancer · doi:10.1002/gcc.70100 · Cited by 4
Progress in the research and development of oncolytic virus therapies
Li, Y. M., Qin, X., Liang, C., & Wang, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1751206 · Cited by 4
Role of Amide Proton Transfer Weighted MRI in Predicting MGMTp Methylation Status, p53-Status, Ki-67 Index, IDH-Status, and ATRX Expression in WHO Grade 4 High Grade Glioma
Durmo, F., Lätt, J., Rydelius, A., Englund, E. M., Salomonsson, T., Liebig, P. A., Bengzon, J., van Zijl, P. C. M., Knutsson, L., & Sundgren, P. C. (2025) · Tomography · doi:10.3390/tomography11060064 · Cited by 4
p53 prophylactic therapy for cancer prevention
Krueger, C., & Sabapathy, K. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01538-z · Cited by 4
Self-citation
A free energy perturbation-assisted machine learning strategy for mimotope screening in neoantigen-based vaccine design
Zhong, Q., Chan, C., Fu, L., & Zhou, R. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf254 · Cited by 4
Clinical application of genomics in Waldenström macroglobulinemia
Branagan, A. R., Lei, M. M., Treon, S. P., & Castillo, J. J. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1881514 · Cited by 4
[Consensus on Postoperative Recurrence Prediction of Non-small Cell Lung Cancer Based on Molecular Markers].
(2022) · PubMed · doi:10.3779/j.issn.1009-3419.2022.102.44 · Cited by 4
MRI radiomics for predicting poor disease-free survival in muscle invasive bladder cancer: the results of the retrospective cohort study
Fan, Z., Zhang, L., Yang, G., Li, S., Guo, J., Bai, J.-J., Wang, B., Yan, L., Wang, L., & Wang, X. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-04028-3 · Cited by 4
Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions
Naeimzadeh, Y., Tajbakhsh, A., & Fallahi, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26260 · Cited by 5
Evaluating targeted therapies in older patients with TP53 -mutated AML
Sabile, J. M. G., Swords, R. T., & Tyner, J. W. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2344057 · Cited by 4
Overall survival in TP53-mutated AML and MDS
Puzo, C. J., Hager, K. M., Rinder, H. M., Weinberg, O. K., & Siddon, A. J. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06054-7 · Cited by 4
Exploration of newly synthesized deferasirox derivatives as potential anti-cancer agents via in-vitro and in-silico approaches
Ullah, M. Z., Hussain, Z., Shakir, S. A., Mahmood, M., Ejaz, S. A., Aziz, M., Fayyaz, A., Iqbal, J., & Mumtaz, A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.137971 · Cited by 4
Downregulation of DDIT4 levels with borneol attenuates hepatotoxicity induced by gilteritinib
Yin, Y., Cao, Y., Zhou, Y., Xu, Z., Luo, P., Yang, B., He, Q., Yan, H., & Yang, X. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116869 · Cited by 4
Digging into lorlatinib resistance in ALK-positive lung cancer: an editorial
Facchinetti, F., & Tiseo, M. (2018) · Chinese Clinical Oncology · doi:10.21037/cco.2018.09.04 · Cited by 4
Broad-spectrum rescue compounds for structural p53 mutations: perspective on ‘Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site’
Wu, J., Chen, S., & Lu, M. M. (2021) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjab007 · Cited by 4
The emerging role of cell cycle protein p53 expression by tumor cells and M2-macrophage infiltration in urinary bladder cancer
Aljabery, F. A.-S., Shabo, I., Saudi, A., Holmbom, M., Olson, H., & Jahnson, S. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.12.005 · Cited by 4
[High expression of MRPL13 promotes cell cycle progression and proliferation of gastric cancer cells by inhibiting p53 signaling to affect long-term prognosis].
Wang, L., Xia, Y., Zhang, Z., Liu, X., Shi, J., Wang, Y., Li, J., Zhnag, X., Geng, Z., Song, X., et al. (2023) · PubMed Central · doi:10.12122/j.issn.1673-4254.2023.09.13 · Cited by 4
Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms
Venugopal, S., & Loghavi, S. (2023) · Pathobiology · doi:10.1159/000534566 · Cited by 4
The changes in the p53 protein across the animal kingdom pointing to its involvement in longevityPreprint
Bartas, M., Brázda, V., Volná, A., Červeň, J., Pečínka, P., & Zawacka‐Pankau, J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.06.080200 · Cited by 4
Artificial Intelligence-Guided Molecular Determinants of PI3K Pathway Alterations in Early-Onset Colorectal Cancer Among High-Risk Groups Receiving FOLFOXPreprint
Diaz, F. C., Waldrup, B., Carranza, F., Manjarrez, S., & Velazquez-Villarreal, E. I. (2025) · medRxiv · doi:10.1101/2025.08.18.25333929 · Cited by 4
Targeting mutant p53: Evaluation of novel anti-p53R175H monoclonal antibodies as diagnostic tools
Spiegelberg, D., Hwang, L., Pua, K. H., Kumar, S. C., Koh, X. Y., Koh, X. H., Selvaraju, R. K., Sabapathy, K., Nestor, M., & Lane, D. P. (2025) · Scientific Reports · doi:10.1038/s41598-024-83871-w · Cited by 3
Self-citation
Mutant p53 Regulates Pyruvate Dehydrogenase Kinase 1 ( PDK1 ) to Promote Proliferation and Migration in Breast Cancer
Ye, Y., Ou, Z., Li, C., Liao, Q., Zeng, Q., Ju, X., Zhang, D., Wei, Y., Zhang, X., Zhang, J., et al. (2025) · Cancer Science · doi:10.1111/cas.70252 · Cited by 3
Immunological Role of TP53 Somatic Mutation Classification in Human Cancers
Fang, J., Yang, Y., Xie, L., & Yin, W. (2023) · Journal of Oncology · doi:10.1155/2023/1904309 · Cited by 3
In-silico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries
Ghosh, D. D., Chowdhury, R. R., Dutta, R., Mukhopadhyay, I., Mukhopadhyay, A., & Roychoudhury, S. (2023) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2023.101209 · Cited by 3
Tumor Budding, p53, and DNA Mismatch Repair Markers in Sinonasal Intestinal-Type Adenocarcinoma: A Retrospective Study Supports the Adverse Prognostic Impact of Tumor Budding
Puccio, S., Azzarello, G., Maffeis, V., Laurino, L., Mairani, E., Conte, F. P., Tessari, N., Cazzador, D., Zanoletti, E., Politi, D., et al. (2024) · Cancers · doi:10.3390/cancers16101895 · Cited by 3
Unlocking the potential of LHPP: Inhibiting glioma growth and cell cycle via the MDM2/p53 pathway
Guo, L., Chen, W., Yue, J., Gao, M., Zhang, J., Huang, Y., Xiong, H., Li, X., Wang, Y., Yuan, Y., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167509 · Cited by 3
Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth
Lv, F., Zhang, L., Ji, C., Peng, L., Zhu, M., Yang, S., Dong, S., Zhou, M., Guo, F., Li, Z., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108167 · Cited by 3
Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies
Wu, J., Song, H., Xiao, S., & Lu, M. M. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00826-7 · Cited by 3
A visual guide to restoring the guardian of the genome
Eisenstein, M. S. (2022) · Nature · doi:10.1038/d41586-022-00566-w · Cited by 3
Autophagy Blockage Reduces the Incidence of Pancreatic Ductal Adenocarcinoma in the Context of Mutant Trp53
Mainz, L., Sarhan, M. A. F. E., Roth, S., Sauer, U., Maurus, K., Hartmann, E., Seibert, H.-D., Rosenwald, A., Diefenbacher, M. E., & Rosenfeldt, M. T. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.785252 · Cited by 3
The crosstalk between ubiquitin-conjugating enzyme E2Q1 and p53 in colorectal cancer: An in vitro analysis
Rasouli, M., Khakshournia, S., Vakili, O., Dastghaib, S., Seghatoleslam, A., & Shafiee, S. M. (2023) · Medical Oncology · doi:10.1007/s12032-023-02039-0 · Cited by 3
Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53
Siddon, A. J., & Weinberg, O. K. (2023) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.07.004 · Cited by 3
Full-atomistic molecular dynamics analysis of p53 active tetramer
Zhou, H., Geng, Y.-Z., & Yan, S. (2023) · Acta Physica Sinica · doi:10.7498/aps.73.20231515 · Cited by 3
Tumor suppressor genes in the tumor microenvironment
Tabanifar, B., Lau, H., & Sabapathy, K. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052049 · Cited by 3
Self-citation
Artificial Intelligence-Guided Molecular Determinants of PI3K Pathway Alterations in Early-Onset Colorectal Cancer Among High-Risk Groups Receiving FOLFOX
Diaz, F. C., Waldrup, B., Carranza, F., Manjarrez, S., & Velazquez-Villarreal, E. I. (2025) · Biomedicines · doi:10.3390/biomedicines13112630 · Cited by 3
Comparison of the effects of synthetic and plant-derived mTOR regulators on healthy human ovarian cells
Sirotkin, A. V., Adamcová, E., Rotili, D., Mai, A., Mlynček, M., Mansour, L. A., Alwasel, S. H., & Harrath, A. H. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.03.048 · Cited by 3
Molecular Characterization and Clinical Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients With TP53 Mutation
Li, Y., Wan, H., & Jing, Y. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.007 · Cited by 3
Uselessness of Serum p53 Antibody for Detecting Colitis-associated Cancer in the Era of Immunosuppressive Therapy
Toritani, K., Kimura, H., Kunisaki, R., Watanabe, J., Kunisaki, C., Ishibe, A., Chiba, S., Inayama, Y., & Endo, I. (2020) · In Vivo · doi:10.21873/invivo.11830 · Cited by 3
Inactivation of Wild-Type p53 by Asparagine Endopeptidase in Glioblastoma: An Opportunity to Target the “Undruggable”
Manfredi, J. J. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz156 · Cited by 3
TP53 Gene Indels Impact on Cancer Outcomes
Guerra, E., & Alberti, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01385 · Cited by 3
TP53 Variant Clusters Stratify the Li-Fraumeni Spectrum and Reveal an Osteosarcoma-Prone SubgroupPreprint
Fischer, N. W., Laverty, B., Alon, N., Montellier, E., Maxwell, K. N., Kratz, C. P., Hainaut, P. L., Kafri, R., & Malkin, D. M. (2024) · medRxiv · doi:10.1101/2024.01.06.23300162 · Cited by 3
A Water‐Stable and Red‐Emissive Radical Cation for Mutp53 Cancer Therapy
Zhou, Z., Qian, J., Liu, K., Zhang, Y., Gao, M., & Tang, B. Z. (2022) · Angewandte Chemie · doi:10.1002/ange.202212671 · Cited by 2
Targeting P53 Gene in Breast Cancer
Abuhagr, A. M., Musa, E. B., Attir, O. A., & Alati, R. M. O. (2023) · Journal Of Advanced Zoology · doi:10.17762/jaz.v44is7.2746 · Cited by 2
Synergistic rescue of temperature‐sensitive p53 mutants by hypothermia and arsenic trioxide
Lu, J., Chen, L., Fatima, Z., Huang, J. J., & Chen, J. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23804 · Cited by 2
Differential effect of plakoglobin in restoring the tumor suppressor activities of p53-R273H vs. p53-R175H mutants
Lo, C. S., Alavi, P., Bassey-Archibong, B. I., Jahroudi, N., & Pasdar, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306705 · Cited by 2
The rise of new targets in melanoma
Bai, X. L., & Flaherty, K. T. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf251 · Cited by 2
Prevalence of Atypical and Subclonal p53 Immunohistochemistry Expression in Mismatch Repair Deficient and/or POLE-Mutant Endometrial Carcinomas with TP53 Mutation
Wang, J., Cai, Y., Wang, J., Fang, J., Pang, J., Zhang, H., Lu, J., Zhang, Z., Wu, H., & Liang, Z. (2025) · Laboratory Investigation · doi:10.1016/j.labinv.2025.104216 · Cited by 2
p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Wang, M., Bieging-Rolett, K. T., Kaiser, A. M., Brady, C. A., Lockhart, J. H., Ferreira, S., Nguyen, K. T., Rajeevan, A., Evans, S. A., Zhao, T., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0525 · Cited by 3
Fibrillarin: bridging ribosome biogenesis and apoptosis in cellular stress and disease
Zhang, Z., Zhang, M., Cao, Z., Zhao, H., Li, X., & Luo, P. (2026) · APOPTOSIS · doi:10.1007/s10495-025-02220-y · Cited by 3
Li-Fraumeni Syndrome
Villani, A., Frébourg, T., & Malkin, D. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-74448-9_1 · Cited by 2
Epitope identification for p53R273C mutant
Zhang, J., Liu, M., Chen, Y., Zhou, Z., Wang, P., Yu, Y., & Jiao, S. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.752 · Cited by 1
Development of machine learning-based malignant pericardial effusion-related model in breast cancer: Implications for clinical significance, tumor immune and drug-therapy
Zhan, W., Hu, H., Hao, B., Zhu, H., Yan, T., Zhang, J., Wang, S., Liu, S., & Zhang, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27507 · Cited by 2
Clinicopathological and prognostic significance of stromal p16 and p53 expression in oral squamous cell carcinoma
Amano, Y., Hasegawa, M., Kihara, A., Matsubara, D., Fukushima, N., Nishino, H., Mori, Y., Inamura, K., & Niki, T. (2025) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2025.152439 · Cited by 2
Pharmacological role of Herba Patriniae and Coix seed in colorectal cancer
Zhang, Y., Wan, H., Shan, G.-Y., Cheng, J.-Y., Liu, Y.-Y., Shi, W., & Li, H. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i3.99673 · Cited by 2
The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia
Ding, W. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.04.001 · Cited by 3
P53, ROS: Redox Regulation Signaling, Metabolic Reprogramming, and Autophagy in Cancer
Bansal, M. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-7342-2_7 · Cited by 2
Small molecule CDS-3078 induces G2/M phase arrest and mitochondria-mediated apoptosis in HeLa cells
Zhang, Y., Li, P., Rong, J., Ge, Y., Hu, C., Bai, X., & Shi, W. M. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9414 · Cited by 2
Frequencies of TP53 Germline Variations and Identification of Two Novel 3’UTR Variants in a Series of Head and Neck Cancer CasesPreprint
Ajaz, S., Muneer, R., Siddiqa, A., & Memon, M. A. (2021) · medRxiv · doi:10.1101/2021.09.09.21263314 · Cited by 2
The guardian of the genome meets a viral master gene regulator at a biomolecular condensatePreprint
Borkosky, S. S., Fassolari, M., Campos-León, K., Rossi, A. H., Salgueiro, M., Pascuale, C. A., Martínez, R. P., Gaston, K., & Gay, G. D. P. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.09.479752 · Cited by 2
Programmable Protein Stabilization with Language Model-Derived Peptide GuidesPreprint
Hong, L., Ye, T., Wang, T., Sri, D., Zhao, L., Watson, R., Vincoff, S., Chen, T., Kholina, K., Goel, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4670386/v1 · Cited by 2
Artificial Intelligence Agent: AI-HOPE-TP53 Enables Pathway-Centric Analysis of TP53-Driven Molecular Alterations in Colorectal Cancer Precision OncologyPreprint
Yang, E.-W., Waldrup, B., & Velazquez-Villarreal, E. I. (2025) · medRxiv · doi:10.1101/2025.05.23.25328251 · Cited by 2

Authors: Sabapathy, K., & Lane, D. P.
Affiliations: National University of Singapore (SG)
Agency for Science, Technology and Research (SG)
Corresponding author: Sabapathy, Kanaga
Lane, David P.
ORCID: Sabapathy, Kanaga
Lane, David P.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2017-09-26
Volume: 15
Issue: 1
Pages: 13-30
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2017.151
OpenAlex: W2759444489
Cited by: 517
References: 178
Citations by year: 2026: 40 · 2025: 67 · 2024: 74 · 2023: 89 · 2022: 57 · 2021: 64 · 2020: 53 · 2019: 41 · 2018: 26 · 2017: 3
FWCI: 3.53
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Research Foundation Singapore
National Medical Research Council
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords: TP53 mutation, mutant p53, p53-targeted therapy, tumour suppressor, cancer therapy resistance, prognostic factors
MeSH terms: Humans, Mutation, Neoplasms, Genes, p53

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks